CA1184501A - Antiparkinsonian agent - Google Patents

Antiparkinsonian agent

Info

Publication number
CA1184501A
CA1184501A CA000411281A CA411281A CA1184501A CA 1184501 A CA1184501 A CA 1184501A CA 000411281 A CA000411281 A CA 000411281A CA 411281 A CA411281 A CA 411281A CA 1184501 A CA1184501 A CA 1184501A
Authority
CA
Canada
Prior art keywords
dops
threo
dopa
disease
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000411281A
Other languages
English (en)
French (fr)
Inventor
Hirotaro Narabayashi
Akira Hayashi
Tomokazu Suzuki
Tomoyoshi Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Application granted granted Critical
Publication of CA1184501A publication Critical patent/CA1184501A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA000411281A 1981-09-22 1982-09-13 Antiparkinsonian agent Expired CA1184501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP150082/1981 1981-09-22
JP56150082A JPS5852219A (ja) 1981-09-22 1981-09-22 パ−キンソン病治療剤

Publications (1)

Publication Number Publication Date
CA1184501A true CA1184501A (en) 1985-03-26

Family

ID=15489114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000411281A Expired CA1184501A (en) 1981-09-22 1982-09-13 Antiparkinsonian agent

Country Status (13)

Country Link
US (1) US4497826A (https=)
JP (1) JPS5852219A (https=)
AU (2) AU556542B2 (https=)
BE (1) BE894451A (https=)
CA (1) CA1184501A (https=)
CH (1) CH650926A5 (https=)
DE (1) DE3235093A1 (https=)
FR (1) FR2513117B1 (https=)
GB (1) GB2106388B (https=)
IT (1) IT1212668B (https=)
NL (1) NL189648C (https=)
NZ (1) NZ201864A (https=)
SE (1) SE462781B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575849B2 (en) * 1983-09-22 1988-08-11 Sumitomo Chemical Company, Limited Pharmaceutical composition and method for treatment of psychomotor excitement
NZ209514A (en) * 1983-09-22 1988-03-30 Sumitomo Chemical Co Pharmaceutical compositions containing erythro-3,4-dihydroxyphenylserine and a decarboxylase inhibitor
JPS6067420A (ja) * 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
JPS60132935A (ja) * 1983-12-20 1985-07-16 Sumitomo Chem Co Ltd フエニルセリン誘導体及びその製造方法
JPS6185318A (ja) * 1984-10-04 1986-04-30 Sumitomo Seiyaku Kk 利尿薬
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
PT99864B (pt) * 1990-12-21 1999-06-30 Schering Ag Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
JP3559572B2 (ja) 1993-01-29 2004-09-02 住友製薬株式会社 急性痛および慢性痛用鎮痛剤
JP3764179B2 (ja) * 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US7786126B2 (en) * 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
CN101657193A (zh) * 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
CN102548957A (zh) 2009-07-01 2012-07-04 大日本住友制药株式会社 制备苏-3-(3，4-二羟基苯基)-l-丝氨酸的方法
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL34687A (en) * 1969-06-18 1973-07-30 Merck & Co Inc Compounds of a-hydrazino-b-acid (3,4-dihydroxyphenyl) -a-converted propionate
US3658968A (en) * 1970-06-11 1972-04-25 Merck & Co Inc Composition and method of treatment
DE2305209A1 (de) * 1972-02-14 1973-08-23 Hoffmann La Roche Pharmazeutisches praeparat
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
US3920728A (en) * 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
CH580059A5 (https=) * 1973-08-22 1976-09-30 Hoffmann La Roche
JPS52125630A (en) * 1976-04-14 1977-10-21 Kyowa Hakko Kogyo Co Ltd Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine
JPS56104815A (en) * 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension

Also Published As

Publication number Publication date
SE8205404D0 (sv) 1982-09-21
DE3235093C2 (https=) 1988-12-29
NL189648C (nl) 1993-06-16
AU8857882A (en) 1983-03-31
JPH0216284B2 (https=) 1990-04-16
AU575267B2 (en) 1988-07-21
GB2106388A (en) 1983-04-13
NL8203594A (nl) 1983-04-18
BE894451A (fr) 1983-03-21
IT1212668B (it) 1989-11-30
GB2106388B (en) 1986-03-26
IT8268118A0 (it) 1982-09-21
SE462781B (sv) 1990-09-03
DE3235093A1 (de) 1983-04-07
SE8205404L (sv) 1983-03-23
US4497826A (en) 1985-02-05
FR2513117A1 (fr) 1983-03-25
NL189648B (nl) 1993-01-18
JPS5852219A (ja) 1983-03-28
AU6750187A (en) 1987-04-16
CH650926A5 (de) 1985-08-30
NZ201864A (en) 1985-12-13
FR2513117B1 (fr) 1986-01-24
AU556542B2 (en) 1986-11-06

Similar Documents

Publication Publication Date Title
CA1184501A (en) Antiparkinsonian agent
JP6119068B2 (ja) 認知障害の処置に有用なα−アミノアミド誘導体
ES2326373T3 (es) Metodos para el tratamiento de la enfermedad de parkinson.
US20220296584A1 (en) Membrane Active Molecules
US4438119A (en) Method for alleviation of extrapyramidal motor disorders
PT1311272E (pt) Novos métodos utilizando inibidores de colinesterase
JP2010520885A (ja) 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
US6946474B2 (en) Nitrogen-containing compounds and their use as glycine transport inhibitors
JPH0643299B2 (ja) 薬剤療法
JP4351909B2 (ja) 薬剤を調製するための、２−オキソ−１−ピロリジン誘導体の使用
US20100016440A1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
CA1267094A (en) Therapeutic drug for dementia
EP1588704A1 (en) Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101049694B1 (ko) 항편두통제로 유용한 알파-아미노아미드 유도체
AU780328B2 (en) Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient
US3969521A (en) Pharmaceutical compositions containing tetrahydroalstonine and method for treating circulation disorders
US3658968A (en) Composition and method of treatment
WO2011035343A2 (en) Phentermine liquid dosage form
US20040186144A1 (en) Use of vitamin B6 to mitigate visual field defects associated with the use of GABAergic drugs in mammals
US5244923A (en) Use of 2-(phenoxypropanolamino) ethoxphenoxy-acetic acid and its derivatives to inhibit gastrointestinal motility
KR890012961A (ko) N-(저급알킬)-2-(3'-우레이도벤질)피롤리딘
US20250195457A1 (en) Pharmaceutical composition for treatment of parkinson's disease
CA2141774A1 (en) Venlafaxine in the inducement of cognition enhancement
JP2005503426A (ja) 抗アルコール中毒剤としてのアミン類
Lang et al. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study

Legal Events

Date Code Title Description
MKEC Expiry (correction)
MKEX Expiry